Perhexiline was identified as a potential therapeutic agent for T-ALL due to its ability to elicit a gene expression signature resembling that induced by HES1 deletion in NOTCH1-induced T-ALL. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.